COMP <GO>
XRAY vs LMAT // ALTMAN Z-SCORE & DEBT/EQUITY
DENTSPLY SIRONA Inc. (NASDAQ) VS. LeMaitre Vascular Inc. (NASDAQ) • 15-METRIC TALLY: XRAY 3
— LMAT 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LMAT
LAST: $9.61 (+1.80%) • MKT CAP: $1.92B
balance-sheet
0.45
LAST: $85.27 (+2.90%) • MKT CAP: $1.95B
balance-sheet
7.30
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XRAY VS. LMAT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XRAY | LMAT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.00% | 71.50% | -21.50 | LMAT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.00% | 14.70% | -25.70 | LMAT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 28.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 12.27% | 4.17% | +8.10 | XRAY | /fcf-yield <GO> |
| Operating Margin | -11.50% | 27.20% | -38.70 | LMAT | /operating-margins <GO> |
| Net Profit Margin | -16.20% | 23.10% | -39.30 | LMAT | /net-margins <GO> |
| Revenue Growth (YoY) | -3.00% | 13.50% | -16.50 | LMAT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 6.68% | 0.93% | +5.75 | XRAY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.45 | 7.30 | -6.85 | LMAT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | LMAT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.1 | 45.4 | +9.70 | XRAY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 28.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.92B | $1.95B | -$34.3M | LMAT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XRAY REV | LMAT REV | XRAY GROSS % | LMAT GROSS % | XRAY FCF | LMAT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.68B | $249.6M | 50.0% | 71.5% | $235.0M | $81.3M |
| FY 2024 | $3.79B | $219.9M | 51.6% | 68.6% | $461.0M | $44.1M |
| FY 2023 | $3.96B | $193.5M | — | — | $377.0M | $36.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XRAY // BETA —
LMAT // BETA —